• Data
    • Overview
    • Clinical notes
    • Images
    • Mother-child
    • Oncology
    • Regulatory grade
    • Truveta Language Model
    • Truveta Studio
  • Genomics
  • Solutions
    • Life science
    • Public health
    • Healthcare
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Events & webinars
    • Newsroom
    • Careers
Get started
Sign in
ASCO 2025: Development and validation of machine learning risk prediction models for detection of early-onset colorectal cancer

ASCO 2025: Development and validation of machine learning risk prediction models for detection of early-onset colorectal cancer

by Truveta staff | May 30, 2025 | Research, Research Insights

Authors: Wilson Lau, PhD ⊕Truveta, Inc, Bellevue, WA,, Youngwon Kim, PhD ⊕Truveta, Inc, Bellevue, WA, Sravanthi Paras, MD ⊕Swedish Medical Center, Seattle, WA, Md Enamul Haque, PhD ⊕Truveta, Inc, Bellevue, WA,, Sara Daraei, PhD ⊕Truveta, Inc, Bellevue, WA, Rajesh Rao,...
ASCO 2025: Changes in colorectal cancer screening and detection following USPSTF expanded recommendations

ASCO 2025: Changes in colorectal cancer screening and detection following USPSTF expanded recommendations

by Truveta Research | May 30, 2025 | Research, Research Insights

Authors: Patricia J. Rodriguez, PhD, MPH ⊕Truveta, Inc, Bellevue, WA Duy Do, PhD ⊕Truveta, Inc, Bellevue, WA, Brianna M. Goodwin Cartwright, MS ⊕Truveta, Inc, Bellevue, WA, Jennifer Liang, MD ⊕Truveta, Inc, Bellevue, WA, Keenan Robbins, MBBS ⊕Washington University...
Truveta Data analysis shows improved outcomes with Impella support in high-risk heart procedures

Truveta Data analysis shows improved outcomes with Impella support in high-risk heart procedures

by Truveta staff | May 21, 2025 | Research

A recent analysis using Truveta Data reveals that patients undergoing high-risk, non-emergency heart procedures (percutaneous coronary intervention, or PCI) with support from the Impella heart pump had better outcomes than those supported with an intra-aortic balloon...
Evaluating recent trends in early measles vaccinations in Texas

Evaluating recent trends in early measles vaccinations in Texas

by Truveta Research | May 16, 2025 | Research, Research Insights

Among children in Texas receiving a first measles vaccine prior to two years of life: In March and April 2025, 20.1% of all first measles vaccines were administered to children early (6-11 months). This is 11.5-fold higher than in 2019, when there were international...
ISPOR 2025: Trends in the prescribing and dispensing of GLP-1 anti-obesity medications among adults with cardiovascular disease

ISPOR 2025: Trends in the prescribing and dispensing of GLP-1 anti-obesity medications among adults with cardiovascular disease

by Truveta Research | May 14, 2025 | Research, Research Insights

Authors: Duy Do, PhD ⊕Truveta, Inc, Bellevue, WA, Karthik Murugiah, MBBS, MHS ⊕Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven,...
ISPOR 2025: Real-world temporal and indication-specific variation in drivers of GLP-1 RA discontinuation 

ISPOR 2025: Real-world temporal and indication-specific variation in drivers of GLP-1 RA discontinuation 

by Truveta Research | May 14, 2025 | Research, Research Insights

Authors: Brianna M. Goodwin Cartwright, MS ⊕Truveta, Inc, Bellevue, WA, Patricia J. Rodriguez, PhD, MPH ⊕Truveta, Inc, Bellevue, WA, Duy Do, PhD ⊕Truveta, Inc, Bellevue, WA, Nicholas Stucky, MD, PhD ⊕Truveta, Inc, Bellevue, WA Side effects were the most common...
« Older Entries
Next Entries »

Share this


Recent posts

  • Non-small cell lung cancer: Biomarkers, treatments, and outcomes in real-world data
  • Johns Hopkins builds research community to explore new frontiers in health using Truveta Data
  • Impact of the CVS GLP-1 formulary change: Trends in switching

Follow Truveta


Sign up for our newsletter

Ready to accelerate your research with representative, complete, and timely real-world data?

Truveta Data

Truveta Genome Project

Solutions

Research

Resources

Blog

Newsroom

Careers

Privacy notice

Contact us

© Truveta 2025

Our website uses cookies to ensure you have the best experience.